January 27, 2020

Eric Rice
Chief Executive Officer
Quanta, Inc.
3606 W. Magnolia Blvd.
Burbank, CA 91505

       Re: Quanta, Inc.
           Registration Statement on Form S-1
           Filed January 15, 2020
           File No. 333-235930

Dear Mr. Rice:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-1 filed January 15, 2020

Cover Page

1.     We note your disclosure on the prospectus cover page that "[t]he
Reselling Stockholders
       may sell all or a portion of the shares being offered pursuant to this
prospectus at fixed
       prices and prevailing market prices at the time of sale, at varying
prices, or at negotiated
       prices." Please revise to clarify here and throughout your prospectus
that the selling
       security holders will sell the shares of common stock at a fixed price
until such time, if
       ever, as the common stock is quoted on the OTC Bulletin Board, the
OTCQX, the
       OCTQB or listed on a securities exchange.
 Eric Rice
FirstName LastNameEric Rice
Quanta, Inc.
Comapany NameQuanta, Inc.
January 27, 2020
Page 2
January 27, 2020 Page 2
FirstName LastName
Executive and Director Compensation, page 29

2.       Please update your filing to include the disclosures required by
Regulation S-K Item 402
         for your last completed fiscal year.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

        Please contact Tim Buchmiller at (202) 551-3635 or Joseph McCann, Legal
Branch
Chief, at (202) 551-6262 with any questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:      W. David Mannheim, Esq.